Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  2016-11-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD009333.PUB3PMID 27880972PMCID PMC6464642
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b

  2016cited by this paper
• Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis.

  2016cited by this paper
• Monitoring von Blutparametern unter verlaufsmodifizierender MS-Therapie

  2016cited by this paper
• Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis.

  2016cited by this paper
• Comparative efficacy of switching to natalizumab in active multiple sclerosis

  2015cited by this paper
• Long-Term Persistence with Injectable Therapy in Relapsing-Remitting Multiple Sclerosis: An 18-Year Observational Cohort Study

  2015cited by this paper
• Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing–remitting multiple sclerosis

  2015cited by this paper
• Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability

  2015cited by this paper
• Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

  2014cited by this paper
• In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: Commentary

  2013cited by this paper
• In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: No

  2013cited by this paper
• Randomized study combining interferon and glatiramer acetate in multiple sclerosis

  2013cited by this paper
• Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.

  2013cited by this paper
• Efficacy and safety of interferon beta-1b sc in older RRMS patients—a posthoc analysis of the BEYOND study

  2013cited by this paper
• Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration

  2013cited by this paper
• Relapse Activity in the CombiRx Trial: Blinded, 7-Year Extension Results (S01.002)

  2013cited by this paper
• Spotlight on the January 1 Issue

  2013cited by this paper
• MRI Outcomes in CombiRx: Blinded, 7-Year Extension Results (S01.003)

  2013cited by this paper
• A Network Meta-Analysis Assessing the Rate of Adverse Events and Drop Outs of Alternative Treatments for Relapsing Forms of Multiple Sclerosis (P01.188)

  2013cited by this paper
• A network meta‐analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis

  2013cited by this paper
• EDSS Changes in CombiRx: Blinded, 7-Year Extension Results for Progression and Improvement (P04.121)

  2013cited by this paper
• Assessing risks of multiple sclerosis therapies.

  2013cited by this paper
• Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis

  2013cited by this paper
• Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years

  2013cited by this paper
• Brain atrophy and lesion load predict long term disability in multiple sclerosis

  2013cited by this paper
• Impact of inflammation on brain volume in multiple sclerosis.

  2012cited by this paper
• Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing–remitting multiple sclerosis

  2012cited by this paper
• The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics.

  2012cited by this paper
• Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial

  2012cited by this paper
• Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.

  2012cited by this paper
• Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis.

  2012cited by this paper
• The CombiRx Trial: A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Participants with Relapsing-Remitting Multiple Sclerosis – Clinical Outcomes (PL02.003)

  2012cited by this paper
• Clinical consequences of MRI activity in treated multiple sclerosis

  2011cited by this paper
• Interferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials.

  2011cited by this paper
• Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

  2011cited by this paper
• Treatments for relapsing–remitting multiple sclerosis: summarising current information by network meta-analysis

  2011cited by this paper
• The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study

  2011cited by this paper
• Interferon β-1b and glatiramer acetate effects on permanent black hole evolution

  2011cited by this paper
• Phase III dose‐comparison study of glatiramer acetate for multiple sclerosis

  2011cited by this paper
• Chapter 10: Addressing reporting biases

  2011cited by this paper
• Glatiramer acetate for multiple sclerosis.

  2010cited by this paper
• Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up.

  2010cited by this paper
• MRI only conversion to multiple sclerosis following a clinically isolated syndrome

  2010cited by this paper
• Interferon-β mechanisms of action in multiple sclerosis

  2010cited by this paper
• [Immunomodulatory treatments for multiple sclerosis: lessons from direct comparative studies].

  2010cited by this paper
• A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis.

  2010cited by this paper
• The mechanism of action of glatiramer acetate treatment in multiple sclerosis

  2010cited by this paper
• Traitements de fond de la sclérose en plaques : enseignements des études randomisées comparatives directes

  2010cited by this paper
• Increasing Use of Disease Modifying Drugs for MS in Canada

  2010cited by this paper
• Glatiramer Acetate

  2010cited by this paper
• Efficacy of treatment of MS with IFN -1b or glatiramer acetate by monthly brain MRI in the BECOME study

  2009cited by this paper
• Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.

  2009cited by this paper
• 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

  2009cited by this paper
• Do interferon beta-1b and glatiramer acetate grow brain?

  2009cited by this paper
• New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate

  2009cited by this paper
• Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.

  2008cited by this paper
• Disease-modifying therapy in multiple sclerosis

  2008cited by this paper
• Comparative studies of glatiramer acetate and interferon beta.

  2008cited by this paper
• Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing–remitting multiple sclerosis in Argentina

  2008cited by this paper
• Interferon-β treatment for relapsing multiple sclerosis

  2008cited by this paper
• Gray matter atrophy is related to long‐term disability in multiple sclerosis

  2008cited by this paper
• Interferon-beta treatment for relapsing multiple sclerosis.

  2008cited by this paper
• REGARD: what can we learn from randomised, open-label, head-to-head studies?

  2008cited by this paper
• Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

  2008cited by this paper
• Temporal trends in the incidence of multiple sclerosis

  2008cited by this paper
• Multiple sclerosis

  2008cited by this paper
• Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

  2005cited by this paper
• Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study

  2005cited by this paper
• Grading quality of evidence and strength of recommendations

  2004cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models.

  2002cited by this paper
• European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis

  2001cited by this paper
• A prospective, open-label treatment trial to compare the effect of IFNβ-1a (Avonex®), IFNβ-1b (Betaseron®), and glatiramer acetate (Copaxone®) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy

  2001cited by this paper
• Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

  2001cited by this paper
• Interferon in relapsing-remitting multiple sclerosis.

  2001cited by this paper
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

  1998cited by this paper
• Bias in meta-analysis detected by a simple, graphical test

  1997cited by this paper
• Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

  1996cited by this paper
• Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

  1995cited by this paper
• A health-related quality of life measure for multiple sclerosis

  1995cited by this paper
• Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

  1995cited by this paper
• Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

  1993cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.

  1989cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper
• Beta blockade during and after myocardial infarction: an overview of the randomized trials.

  1985cited by this paper
• New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

  1983cited by this paper
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper
• Demyelinating Disorders (dn Bourdette and M Cameron, Section Editors) Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices

  year unknowncited by this paper

• Real‐World Comparison of High‐Efficacy Versus Non‐High‐Efficacy Therapies in Multiple Sclerosis

  2025cites this paper
• Interferon-β and interleukin-6 exert opposing effects on Foxp3 acetylation to control regulatory T cell induction

  2025cites this paper
• Structure based in silico screening of natural Vitamin D analogs for targeted and safer treatment of resistant multiple sclerosis

  2025cites this paper
• Comparison of Pharmacological Therapies in Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis

  2023cites this paper
• Potential of Nano-Engineered Stem Cells in the Treatment of Multiple Sclerosis: A Comprehensive Review

  2023cites this paper
• Beneficial Effect of Melatonin Alone or in Combination with Glatiramer Acetate and Interferon β-1b on Experimental Autoimmune Encephalomyelitis

  2022cites this paper
• Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)—a systematic review protocol

  2022cites this paper
• Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II

  2022cites this paper
• Sphingosine-1-phosphate receptor modulators versus interferon beta for the treatment of relapsing–remitting multiple sclerosis: findings from randomized controlled trials

  2022cites this paper
• Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database

  2022cites this paper
• Interferon-β acts directly on T cells to prolong allograft survival by enhancing regulatory T cell induction through Foxp3 acetylation.

  2022cites this paper
• Adherence to Therapy in Patients with Multiple Sclerosis—Review

  2022cites this paper
• Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)

  2022cites this paper
• Immunopathogenesis, Diagnosis, and Treatment of Multiple Sclerosis: A Clinical Update.

  2022cites this paper
• Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target

  2022cites this paper
• Off-Adherence Keeping (OAK) observational study: intentional off-adherence immunomodulatory multiple sclerosis treatment.

  2022cites this paper
• The role of immune semaphorins in the pathogenesis of multiple sclerosis: Potential therapeutic targets.

  2021cites this paper
• Advances in the Treatment of Multiple Sclerosis.

  2021cites this paper
• Interferon-β Is Less Effective Than Other Drugs in Controlling the Rate of Retinal Ganglion Cell Loss in MS

  2021cites this paper
• Switching treatments in clinically stable relapsing remitting multiple sclerosis patients planning for pregnancy

  2021cites this paper
• Using Mnemonic in Management of Multiple Sclerosis

  2021cites this paper
• Inhalation of Dimethyl Fumarate-encapsulated solid lipid nanoparticles attenuate clinical signs of Experimental Autoimmune Encephalomyelitis and pulmonary inflammatory dysfunction in mice.

  2021cites this paper
• Long‐term effect of first‐line injectable multiple sclerosis treatments: Input of a time‐dependent propensity score

  2020cites this paper
• Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort

  2020cites this paper
• The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population

  2019cites this paper
• The Effect of Disease Modifying Therapies on Disability Progression in Multiple Sclerosis: A Systematic Overview of Meta-Analyses

  2019cites this paper
• Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use

  2019cites this paper
• Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2

  2019cites this paper
• Sephin1, which prolongs the integrated stress response, is a promising therapeutic for multiple sclerosis

  2019cites this paper
• Sequencing of disease-modifying therapies for relapsing–remitting multiple sclerosis: a theoretical approach to optimizing treatment

  2018cites this paper
• Transtentorial herniation from tumefactive multiple sclerosis mimicking primary brain tumor

  2018cites this paper
• Cholinergic and purinergic systems: A key to multiple sclerosis?

  2018cites this paper
• Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients

  2018cites this paper
• Kallikrein–Kinin System Suppresses Type I Interferon Responses: A Novel Pathway of Interferon Regulation

  2018cites this paper
• Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort

  2017cites this paper
• A Comprehensive Review on Copemyl®

  2017cites this paper
• Adherence to disease‐modifying therapies for multiple sclerosis and subsequent hospitalizations

  2017cites this paper
• White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis

  2016cites this paper
• Monitoring von Blutparametern unter verlaufsmodifizierender MS-Therapie

  2016cites this paper